Outcomes Following Modern Treatment for Osteosarcoma: The Cook Children's Experience

The purpose of this study is to evaluate patient and tumor characteristics, treatments, and outcomes of patients at Cook Children’s Medical Center (CCMC) who were diagnosed with primary osteosarcoma from January 1, 1992 to December 31, 2013. Prior to the use of systemic chemotherapy, the survival rate for osteosarcoma patients was poor at 15-20% for two year survival. Current five year survival is more than 60% in non-metastatic disease with the addition of systemic chemotherapy. However, patients with metastatic disease at diagnosis have a lower 5 year survival of about 30%. This study will evaluate the outcomes of patients with osteosarcoma at CCMC relative to the outcomes noted at other institutions and in previous literature. It will also evaluate various potential prognostic factors to determine if they significantly affect patient outcomes. Researchers conducted a comprehensive retrospective chart review with the patients abstracted from the Cook Children’s Cancer Registry. The population consists of patients diagnosed with and treated for primary osteosarcoma at CCMC from 1992-2013. The 5 year overall survival for the population is 66.9% ± 6.1. The 5 year Event Free Survival for the population is 62.2% ± 6.6. The 5 year survival for patients with metastases at diagnosis is 50% ± 13.9. The 5 year survival for patients without metastases at diagnosis is 72.3 % ± 6.8. The 5 year survival of patients diagnosed from 1995 to 2003 is 70.0% ± 8.9. The 5 year survival for patients diagnosed from 2004 to 2013 is 64.2% ± 8.8. Survival rates for patients diagnosed with osteosarcoma at CCMC are consistent with the literature. Survival rates have not changed in the past 20 years for osteosarcoma.